{"id":"W4282967222","doi":"10.1158/1538-7445.am2022-ct007","title":"Abstract CT007: PETRA: First in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients (pts) with BRCA1/2, PALB2 or RAD51C/D mutations","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine; Internal medicine; Tolerability; Prostate cancer; Olaparib; Oncology; Pharmacodynamics; Response Evaluation Criteria in Solid Tumors; Pharmacokinetics; Progressive disease; PARP inhibitor; Cancer; Gastroenterology; Clinical trial; Phases of clinical research; Adverse effect; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001261508,0.0001854266,0.0003886809,0.0007041548,0.0004160557,0.00003586892,0.0002705398,0.0001017452,0.001237483],"category_scores_gemma":[0.0002495833,0.0001429021,0.00006996873,0.002510347,0.0002940931,0.0001919407,0.0001036573,0.001380693,0.000003994946],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003576321,"about_ca_system_score_gemma":0.00144528,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0046212,"about_ca_topic_score_gemma":0.05435264,"domain_scores_codex":[0.9964259,0.0004544937,0.0006848318,0.0005078638,0.001398028,0.0005288507],"domain_scores_gemma":[0.9986386,0.0003485801,0.0001900853,0.000426861,0.0003031342,0.00009271939],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1465098,0.008621599,0.7289718,0.0007233545,0.0002238742,0.0001907536,0.02366487,0.01995455,0.03306123,0.0004053288,0.03306853,0.004604315],"study_design_scores_gemma":[0.2220645,0.006428138,0.7300905,0.00129794,0.00003024117,0.000008303758,0.003386629,0.0006783798,0.02581733,0.0002780424,0.009379674,0.000540369],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9932565,0.0001723483,0.000001501451,0.002370312,0.0003100666,0.003127885,0.00008547668,0.000013668,0.00066221],"genre_scores_gemma":[0.9954973,0.0001291539,0.00001584147,0.000121988,0.0003904154,0.003481021,0.00008987403,0.00004504493,0.0002292928],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07555464,"threshold_uncertainty_score":0.9996755,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1556164151283519,"score_gpt":0.4129968895698667,"score_spread":0.2573804744415147,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}